- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02285205
A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
Lobeglitazone is highly selective peroxisome proliferator-activated receptor-gamma agonist that decreases insulin resistance in the periphery and liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. In vivo, It demonstrates that Lobeglitazone improves even more glycemic and lipid control in comparison to rosiglitazone and pioglitazone. Currently, thiazolidinediones such as pioglitazone is the only drug which is considered as an effective therapeutic agent for improving non-alcoholic fatty liver disease (NALFD) in type 2 diabetes (T2D).
The aim of this multicenter, prospective, open-labeled, single-arm, exploratory phase 4 study is to evaluate the efficacy and safety of Lobeglitazone once daily for 24 weeks on intrahepatic fat contents assessed by transient elastography (fibroscan) in T2D with NAFLD.
Fifty subjects with T2D and NAFLD will take Lobeglitazone (0.5mg/tablet, orally, 1 tablet once daily) for 24 weeks.
Primary endpoint is changes from baseline in controlled attenuation parameters (CAP) measured by transient elastography (fibroscan) after treatment with Lobeglitazone.
Secondary endpoints are changes from baseline in glycemic profiles (HbA1c, Glycated albumin), Lipid parameters (Total Cholesterol, Triglycerides, HDL-C, LDL-C), Liver function parameters (AST, ALT, r-GT), and adverse events during the trial.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type Ⅱ diabetes mellitus
- Non-alcoholic fatty liver disease: subjects who have CAP(Controlled Attenuation Parameter) ≥ 250dB/m measured by transient elastography (fibroscan) at screening test
- Age ≥ 20 years
- Patients who have not been taking any oral hypoglycemic agent for more than 12 weeks with HbA1c 7.0 to 8.5% at screening test or who have been taking metformin monotherapy for at least 8 weeks with HbA1c 7 to 9% at screening test
- Agreement with written informed consent
Exclusion Criteria:
- Patients whose alcohol consumption >210g/week for males and 140g/week for females
- chronic B viral hepatitis, chronic C viral hepatitis, Type I diabetes, or secondary diabetes
- having a history of acute or chronic metabolic acidosis including diabetic ketoacidosis
- patients who have been taking other oral hypoglycemic agents except metformin or insulin within recent 8 weeks
- who experienced hypersensitivity reaction against metformin or glitazone drugs
- who has been treated with corticosteroids for at least 14 days within 2 month prior to Screening
- having a history of lactic acidosis
- having genetic predispositions such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
- who are in condition of malnutrition, starvation, cachexia, severe infection, major trauma, hypopituitarism, or adrenal insufficiency
- diagnosed with cancer within 2 years or having chemo or radiotherapy for cancer treatment
- a history of drug abuse or chronic alcoholism
- a history of heart failure (NYHA class III and IV) or uncontrolled arrhythmia
- a history of acute cardiovascular or cerebrovascular disease within 12 weeks prior to Screening (unstable angina, myocardial infarction, transient ischemic attack, cerebral infarct, cerebral hemorrhage, coronary bypass, percutaneous coronary intervention)
- Renal dysfunction: Serum creatinine greater than 1.5mg/dl for males and 1.4mg/dl for females.
- Anemia less than 10.5g/dl for any reason
- Pregnant women or nursing mothers
- Fertile women who not practice contraception with appropriate methods
- in treatment concomitant drug from other clinical trials within 4 weeks from enrollment
- who did not agree with written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lobeglitazone
|
Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes from baseline in controlled attenuation parameters (CAP)
Time Frame: 24 weeks
|
Changes from baseline in controlled attenuation parameters (CAP) measured by transient elastography (fibroscan) after treatment with Lobeglitazone
|
24 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2014-0778
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Oral administration of Lobeglitazone
-
Medicines for Malaria VentureRichmond Pharmacology LimitedCompleted
-
Milton S. Hershey Medical CenterCompleted
-
Glock Health, Science and Research GmbHUnknownIrritable Bowel Syndrome With Diarrhea (IBS-D)Austria
-
Basilea PharmaceuticaCompletedNeoplasmsBelgium, United Kingdom, Germany, Switzerland
-
Sakarya UniversityUnknownOral Colostrum Administration in Very Low Birth Weight Premature InfantsTurkey
-
Taiho Oncology, Inc.RecruitingNon-Small Cell Lung CancerUnited States, France, Italy, Korea, Republic of, Japan, Spain, Germany, Netherlands, United Kingdom
-
Centre Hospitalier Universitaire DijonCompletedIntubated-ventilated Patients in the Intensive Care UnitFrance
-
Chong Kun Dang PharmaceuticalUnknownDiabetes Mellitus, Type IIKorea, Republic of
-
Children's Hospital of Fudan UniversityFudan UniversityCompletedInfant, Very Low Birth Weight
-
Loyola UniversityRecruitingStress | Infant DevelopmentUnited States